Nephrogenex initiates pivotal oral Pyridorin Phase 3 study NephroGenex announced it has initiated patient enrollment in the first of two pivotal Phase 3 studies in the PIONEER program for oral Pyridorin. The trial will evaluate the safety and efficacy of Pyridorin in slowing disease progression in patients with diabetic nephropathy.
NephroGenex names Jaikrishna Patel as Chief Medical Officer NephroGenex (NRX) announced the appointment of Dr. Jaikrishna Patel to the position of Chief Medical Officer. Dr. Patel will help guide the company’s Phase 3 PIONEER program with oral Pyridorin for the treatment of diabetic nephropathy, and the development of an intravenous formulation of Pyridorin for acute kidney injury. Patel has held numerous positions of increasing responsibility at GlaxoSmithKline (GSK) and its predecessor companies, most recently serving as Vice President of Cardiovascular and Cardiovascular Metabolism, Global Regulatory Affairs.